Glenmark signs cancer drug licensing deal with Hengrui Pharma for $18 million upfront payment
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
The entity will undertake the installation, operation, and maintenance of sewage treatment plants
Collaboration matches more eligible patients, including those with rare and complex diseases, to appropriate clinical trials
The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
This predictive technology empowers people with diabetes to take preventive action before complications arise
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Subscribe To Our Newsletter & Stay Updated